Discrepancies in Determinations of the Ginzburg-Landau Parameter

Long-standing discrepancies within determinations of the Ginzburg-Landau parameter $\kappa$ from supercritical field measurements on superconducting microspheres are reexamined. The discrepancy in tin is shown to result from differing methods of analyses, whereas the discrepancy in indium is a consequence of significantly differing experimental results. The reanalyses however confirms the lower $\kappa$ determinations to within experimental uncertainties.Comment: submitted to Phys. Rev.

Measurement of Free Tropospheric Aerosols in the North Atlantic at the Pico Mountain Observatory.

AAAR 31st Annual Conference. Minneapolis, Minnesota, October 8-12, 2012.The Pico Mountain Observatory is located at 2225 m amsl on an inactive volcano at Pico Island in the Azores archipelago in the North Atlantic ~3900 km east and downwind of North America (38º28'15''N; 28º24’'14''W). The unique location of the Observatory enables sampling of free tropospheric air transported over long, intercontinental distances and is rarely affected by local emissions. The Observatory is affected mainly by North American outflow after its trans-Atlantic transport. Therefore, its location is ideal for observations of long-range transported pollutants emitted from anthropogenic and biogenic continental sources. The composition of continental pollution outflow is altered during transport by mixing, chemical reactions, phase changes, and removal processes. Thus, the properties of aerosol and trace gases in downwind regions are impacted by the outflow of pollutants, their chemical transformation, and sinks. In previous work, the sampled air-mass measurements (including CO, O3, NOx, NOy, NMHC, black carbon and aerosol optical size) and the simulations of their dispersion indicated outflow of North American tropospheric ozone and its precursors. Although the measurements have been crucial in explaining the evolution of North American gaseous pollution, little is known regarding the nature of the aged aerosol. New work is currently underway at the Observatory to provide chemical characterization of the intercepted free tropospheric aerosols. Here, we show the preliminary results of the free tropospheric aerosol composition and its physical properties. Samples were collected using high-volume filter samplers with quartz filters and analyzed for organic and elemental carbon (OC and EC, respectively). We compare the observed OC and EC values to the collocated measurements of gas- and particle-phase species, meteorological parameters and to the values found in current literature. We highlight the future work in which we will select filter samples based on the arrival of highly polluted air masses from anthropological or biomass burning emissions for further detailed analysis

Ten Years of Black Carbon Measurements in the North Atlantic at the Pico Mountain Observatory, Azores (2225m asl).

45th annual Fall Meeting, AGU. San Francisco, California, 3-7 December.The Pico Mountain Observatory is located in the summit caldera of the Pico mountain, an inactive volcano on the Pico Island in the Azores, Portugal (38.47°N, 28.40°W, Altitude 2225m asl). The Azores are often impacted by polluted outflows from the North American continent and local sources have been shown to have a negligible influence at the observatory. The value of the station stems from the fact that this is the only permanent mountaintop monitoring station in the North Atlantic that is typically located above the marine boundary layer (average MBL heights are below 1200 m and rarely exceed 1300 m) and often receives air characteristic of the lower free troposphere. Measurements of black carbon (BC) mass have been carried out at the station since 2001, mostly in the summer seasons. Here we discuss the BC decadal dataset (2001-2011) collected at the site by using a seven-wavelength AE31 Magee Aethalometer. Measured BC mass and computed Angstrom exponent (AE) values were analysed to study seasonal and diurnal variations. There was a large day-to-day variability in the BC values due to varied meteorological conditions that resulted in different diurnal patterns for different months. The daily mean BC at this location ranged between 0 and ~430 ngm-3, with the most frequently occurring value in the range 0-100 ngm-3. The overall mean for the 10 year period is ~24 ngm-3, with a coefficient of variation of 150%. The BC values exhibited a consistent annual trend being low in winter months and high in summer months, barring year to year variations. To differentiate between BC and other absorbing particles, we analyzed the wavelength dependence of aerosol absorption coefficient and determined a best-fit exponent i.e., the Ångström exponent, for the whole dataset. Visible Ångström exponent (AE: 470-520-590-660 nm) values ranged between 0 and 3.5, with most frequently occurring values in the range 0.85 to 1.25. By making use of the aethalometer light attenuation measurements at different wavelengths and Hysplit back trajectories, we divided the data into two categories. One for periods characterized by AE values close to 1; these periods are typically correlated with back trajectories originating from Canada, North America or northern Europe, indicating the dominance of BC on the light attenuation. Another characterized by AE values substantially different from 1; these periods correlated with back trajectories originating from dust-prone regions (e.g., the Sahara desert).The above measurements, with the aid of ancillary satellite and ground-based measurements will be employed in estimating the radiaitve effects of BC in the North Atlantic

Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis – a comprehensive review

Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studies of patients with moderate-to-severe disease. In a phase 2b dose-ranging study of baricitinib in combination with traditional disease-modifyingantirheumatic drugs (DMARDs) in RA patients, magnetic resonance imaging showed that baricitinib 2 mg or 4 mgonce daily provided dose-dependent suppression of synovitis, osteitis, erosion and cartilage loss at weeks 12 and 24versus placebo. These findings correlated with clinical outcomes and were confirmed in three phase 3 studies (RA-BEGIN, RA-BEAM and RA-BUILD) using X-rays to assess structural joint damage. In patients naïve to DMARDs (RA-BEGINstudy), baricitinib 4 mg once daily as monotherapy or combined with methotrexate produced smaller mean changesin structural joint damage than methotrexate monotherapy at week 24. Differences versus methotrexate werestatistically significant for combined therapy. In patients responding inadequately to methotrexate (RA-BEAM study),baricitinib 4 mg plus background methotrexate significantly inhibited structural joint damage at week 24 versus placebo, and the results were comparable to those observed with adalimumab plus background methotrexate. Inpatients responding inadequately to conventional synthetic DMARDs (csDMARDs; RA-BUILD study), baricitinib 4 mgagain significantly inhibited radiographic progression compared with placebo at week 24. Benefits were also observedwith baricitinib 2 mg once daily, but the effects of baricitinib 4 mg were more robust. The positive effects of baricitinib4 mg on radiographic progression continued over 1 and 2 years in the long-term extension study RA-BEYOND, withsimilar effects to adalimumab and significantly greater effects than placebo. Findings from the phase 3 studies ofpatients with RA were supported by preclinical studies, which showed that baricitinib has an osteoprotective effect, increasing mineralisation in bone-forming cells. In conclusion, baricitinib 4 mg once daily inhibits radiographic jointdamage progression in patients with moderate-to-severe RA who are naïve to DMARDs or respond inadequately to csDMARDs, including methotrexate, and the beneficial effects are similar to those observed with adalimumab

Reconstruction of Northern Hemisphere 1950–2010 atmospheric non-methane hydrocarbons

The short-chain non-methane hydrocarbons (NMHC) are mostly emitted into the atmosphere by anthropogenic processes. Recent studies have pointed out a tight linkage between the atmospheric mole fractions of the NMHC ethane and the atmospheric growth rate of methane. Consequently, atmospheric NMHC are valuable indicators for tracking changes in anthropogenic emissions, photochemical ozone production, and greenhouse gases. This study investigates the 1950–2010 Northern Hemisphere atmospheric C₂–C₅ NMHC ethane, propane, <i>i</i>-butane, <i>n</i>-butane, <i>i</i>-pentane, and <i>n</i>-pentane by (a) reconstructing atmospheric mole fractions of these trace gases using firn air extracted from three boreholes in 2008 and 2009 at the North Greenland Eemian Ice Drilling (NEEM) site and applying state-of-the-art models of trace gas transport in firn, and by (b) considering eight years of ambient NMHC monitoring data from five Arctic sites within the NOAA Global Monitoring Division (GMD) Cooperative Air Sampling Network. Results indicate that these NMHC increased by ~40–120% after 1950, peaked around 1980 (with the exception of ethane, which peaked approximately 10 yr earlier), and have since dramatically decreased to be now back close to 1950 levels. The earlier peak time of ethane vs. the C₃–C₅ NMHC suggests that different processes and emissions mitigation measures contributed to the decline in these NMHC. The 60 yr record also illustrates notable increases in the ratios of the isomeric <i>iso-/n</i>-butane and <i>iso-/n</i>-pentane ratios. Comparison of the reconstructed NMHC histories with 1950–2000 volatile organic compounds (VOC) emissions data and with other recently published ethane trend analyses from ambient air Pacific transect data showed (a) better agreement with North America and Western Europe emissions than with total Northern Hemisphere emissions data, and (b) better agreement with other Greenland firn air data NMHC history reconstructions than with the Pacific region trends. These analyses emphasize that for NMHC, having atmospheric lifetimes on the order of < 2 months, the Greenland firn air records are primarily a representation of Western Europe and North America emission histories

Gigwa v2—Extended and improved genotype investigator

The study of genetic variations is the basis of many research domains in biology. From genome structure to population dynamics, many applications involve the use of genetic variants. The advent of next-generation sequencing technologies led to such a flood of data that the daily work of scientists is often more focused on data management than data analysis. This mass of genotyping data poses several computational challenges in terms of storage, search, sharing, analysis, and visualization. While existing tools try to solve these challenges, few of them offer a comprehensive and scalable solution. Gigwa v2 is an easy-to-use, species-agnostic web application for managing and exploring high-density genotyping data. It can handle multiple databases and may be installed on a local computer or deployed as an online data portal. It supports various standard import and export formats, provides advanced filtering options, and offers means to visualize density charts or push selected data into various stand-alone or online tools. It implements 2 standard RESTful application programming interfaces, GA4GH, which is health-oriented, and BrAPI, which is breeding-oriented, thus offering wide possibilities of interaction with third-party applications. The project home page provides a list of live instances allowing users to test the system on public data (or reasonably sized user-provided data). This new version of Gigwa provides a more intuitive and more powerful way to explore large amounts of genotyping data by offering a scalable solution to search for genotype patterns, functional annotations, or more complex filtering. Furthermore, its user-friendliness and interoperability make it widely accessible to the life science community

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

Objective: To evaluate the efficacy and safety of secukinumab, a fully human, anti-interleukin (IL)-17A monoclonal antibody, in patients with psoriatic arthritis (PsA). Methods: 42 patients with active PsA fulfilling ClASsification for Psoriatic ARthritis (CASPAR) criteria were randomly assigned (2:1) to receive two intravenous secukinumab doses (10 mg/kg; n=28) or placebo (n=14) 3 weeks apart. The primary endpoint was the proportion of American College of Rheumatology (ACR) 20 responses at week 6 for secukinumab versus placebo (one-sided p<0.1). Results: Primary endpoint: ACR20 responses at week 6 were 39% (9/23) for secukinumab versus 23% (3/13) for placebo (p=0.27). ACR20 responses were greater with secukinumab versus placebo at week 12 (39% (9/23) vs 15% (2/13), p=0.13) and week 24 (43% (10/23) vs 18% (2/11), p= 0.14). At week 6, ‘good’ European League Against Rheumatism response was seen in 21.7% (5/23) secukinumab versus 9.1% (1/11) placebo patients. Compared with placebo at week 6, significant reductions were observed among secukinumab recipients for C reactive protein (p=0.039), erythrocyte sedimentation rate (p=0.038), Health Assessment Questionnaire Disability Index (p=0.002) and Short Form Health Survey (SF-36; p=0.030) scores. The overall adverse event (AE) frequency was comparable between secukinumab (26 (93%)) and placebo (11 (79%)) recipients. Six serious AEs (SAEs) were reported in four secukinumab patients and one SAE in one placebo patient. Conclusions: Although the primary endpoint was not met, clinical responses, acute-phase reactant and quality of life improvements were greater with secukinumab versus placebo, suggesting some clinical benefit. Secukinumab exhibited satisfactory safety. Larger clinical trials of secukinumab in PsA are warranted

The properties of the three-nucleon system with the dressed-bag model for nn interaction. I: New scalar three-body force

A multi-component formalism is developed to describe three-body systems with nonstatic pairwise interactions and non-nucleonic degrees of freedom. The dressed-bag model for $NN$ interaction based on the formation of an intermediate six-quark bag dressed by a $\sigma$-field is applied to the $3N$ system, where it results in a new three-body force between the six-quark bag and a third nucleon. Concise variational calculations of $3N$ bound states are carried out in the dressed-bag model including the new three-body force. It is shown that this three-body force gives at least half the $3N$ total binding energy, while the weight of non-nucleonic components in the $^3$H and $^3$He wavefunctions can exceed 10%. The new force model provides a very good description of $3N$ bound states with a reasonable magnitude of the $\sigma NN$ coupling constant. The model can serve as a natural bridge between dynamical description of few-nucleon systems and the very successful Walecka approach to heavy nuclei and nuclear matter.Comment: 26 pages, Latex, 7 figure

Beamsplitting using self-imaging

The production of a variable array of optical point sources from a single point source can be achieved through the self-imaging properties inherent in a rectangular waveguide. Two prototype devices, based upon this concept, were designed and constructed. The resulting output patterns are discussed along with future design considerations and applications